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Abstract
The correlation between hepatitis C virus (HCV) genomic sequences and circulating HCV RNA levels was assessed to investigate the
genetic elements affecting viral load. The interferon sensitivity-determining region (ISDR) sequence and the serum viral load were strongly
correlated in 226 patients examined. Analysis of the entire HCV genome from six patients (three with a high and the others with a low viral
load) with similar ISDR sequences identified several candidate residues associated with viral load. The amino acid (aa) sequences of these
candidate residues and flanking regions in 67 additional patients revealed that only the residue at aa 962 varied significantly between the
HCV patients with low and high serum loads (P 0.042). At this position, alanine was observed more frequently in the patients with a high
viral load. In conclusion, our results strongly suggest that serum HCV RNA loads are inversely correlated with amino acid substitutions in
the ISDR, and aa 962 was identified as a possible second determinant of serum HCV RNA load.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Hepatitis C virus (HCV)1 is one of the most important
pathogens of chronic hepatitis (Major and Feinstone, 1997;
Choo et al., 1989). Chronic hepatitis C often results in liver
cirrhosis and the development of hepatocellular carcinoma
(Kiyosawa et al., 1990; Tong et al., 1995) and, therefore, its
treatment is an important clinical issue. Currently, inter-
feron (IFN)-based regimens, with or without ribavirin, are
the only therapies that can eradicate HCV in some patients
(Chayama et al., 1991; Shindo et al., 1992; Di Bisceglie and
Hoofnagle, 2002). Accordingly, the factors affecting the
efficacy of IFN have been researched vigorously (Tubota et
al., 1994; Mita et al., 1994; Hino et al., 1994; Pawlotsky et
al., 1996; Yamada et al., 1995). We reported that the num-
ber of amino acid substitutions in the interferon sensitivity-
determining region (ISDR) in the NS5A of HCV genotype
1b (HCV-1b) predicts the outcome of IFN therapy (Eno-
moto et al., 1995, 1996; Kurosaki et al., 1997). Along with
the number of substitutions in the ISDR, the serum HCV
viral load also is reported to be an important factor predict-
ing the effectiveness of IFN therapy (Pawlotsky, 2002).
While our previous reports demonstrated that ISDR substi-
tution numbers correlate with serum HCV viral loads (Wa-
tanabe et al., 2001), the relationship between the two vari-
ables has not been examined in more detail. Furthermore,
other than the ISDR, genomic regions of HCV that are
associated with serum viral loads have not been identified.
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The clarification of such sequence elements may contribute
to our understanding of the mechanism of HCV replication
and the nature of chronic hepatitis C.
In the present study, we examined first the correlation
between the number of ISDR amino acid substitutions and
circulating viral load measured by different techniques in
chronic hepatitis C patients infected with HCV-1b. Subse-
quently, we searched for sequence elements other than the
ISDR that correlate with circulating viral levels, through an
analysis of six (three from patients with high and three from
patients with with low viral loads) full-length HCV-1b se-
quences. After identification of such elements, their validity
was confirmed statistically in a large group of patients with
chronic hepatitis C.
Results
Relationship between the ISDR and circulating viral loads
Of the 226 patients, 108 had wild-type ISDR sequences
(no amino acid substitution compared with HCV-J (Kato et
al., 1990)), 87 had the intermediate type (one to three amino
acid substitutions), and 31 had the mutant type (four or more
amino acid substitutions). The proportions of the three types
were comparable to those in our previous report (Enomoto
et al., 1996).
Fig. 1 (viral load measured by the branched DNA
(bDNA) method) and Fig. 2 (viral load measured by the
Amplicor method) show the relationship between the ISDR
and circulating HCV viral loads. The number of amino acid
substitutions in the ISDR showed a strong inverse correla-
tion with the circulating viral load, when determined using
both the bDNA method (P  0.0001, Spearmann’s rank
test, Fig. 1) and the Amplicor method (P  0.0001, Spear-
man’ rank test, Fig. 2). Although 4 of 31 (13%) patients
with the mutant type had less than 10 kcopy/ml, no patient
among the 108 (0%) with the wild type had less than 10
kcopy/ml, using the Amplicor method. In contrast, although
31 of the 108 (29%) patients with the wild type had more
than 10 MEq/ml, only 1 of the 31 (3%) patients with the
mutant type had more than 10 MEq/ml. These results sug-
gest that, as the number of substitutions in the ISDR in-
creases, the serum viral load has a tendency to decrease.
However, of the patients with no or one substitution in
the ISDR, no differences in viral loads were observed be-
tween the two groups using either method (P  0.13 by
bDNA method, P  0.19 by Amplicor method, Mann–
Whitney U test). Therefore, patients with no and one ISDR
substitution belong to a homogeneous group with respect to
circulating viral load.
Full-length HCV sequence analysis in patients with 0 or 1
amino acid substitution in the ISDR
We searched for other genomic regions of HCV that
correlate with the circulating viral load. Sera from six rep-
resentative patients with chronic hepatitis C attributable to
HCV-1b infection and with no or one substitution in ISDR
were analyzed to determine the full-length HCV sequence.
This approach enabled us to exclude the effect of the ISDR
on viral load and allowed us to identify other sequence
elements that are related to circulating viral load. Fig. 3
shows the amino acid alignment of the ISDR from all six
patients. Each has no or one amino acid substitution in the
ISDR. Of these six patients, three had a high circulating
viral load (15 MEq/ml by the bDNA method; high-titer
Fig. 1. Relationship between amino acid substitutions in the ISDR and circulating viral loads, determined by the branched DNA method. The number of amino
acid substitutions in the ISDR correlated inversely with the circulating viral loads (P  0.0001 by Spearmann’s rank test).
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group), while the other group had a low circulating viral
load (0.5 MEq/ml by the bDNA method; low-titer group).
After alignment of the full-length HCV sequences,
amino acid (for coding region) or nucleotide (for noncoding
region) usage was compared in the high- and low-titer
groups for each residue of the entire HCV genome. Between
these two groups, a “complete difference” in amino acid
(aa) usage was demonstrated at aa 708 (in E2, alanine in the
high-titer group vs valine, serine, or threonine in the low-
titer group), aa 962 (in NS2, alanine in the high-titer group
vs threonine, lysine, or valine in the low-titer group), aa
1158 (in NS3, valine in the high-titer group vs isoleucine in
the low-titer group), and aa 1641 (in NS4A, isoleucine in
the high-titer group vs valine in the low-titer group) (Fig. 4).
No such “complete differences” were observed in the 5 and
3 noncoding regions or X-tail.
To rule out the possibility that the four amino acid
residues described above were not of significance, and to
validate the relationship between these amino acid residues
and the circulating viral loads, we determined the sequences
flanking the four amino acids in 67 patients who had no or
one substitution in the ISDR (Table 1). Of these, 10 patients
had a low viral load (0.5 MEq/ml). For each amino acid
position, the median serum HCV RNA (by the bDNA
method) was compared with respect to amino acid usage.
For example, for aa 1641, the median serum HCV RNA
levels were compared between patients who had isoleucine
at aa 1641 and those who had valine. If patients with a
valine residue had significantly smaller amounts of serum
HCV RNA (confirming the initial observation), then aa
1641 would be considered to be associated with circulating
viral load.
Table 2 shows the results of the comparison described
above. Of the four amino acid residues, amino acid usage at
aa 962 correlated with serum HCV RNA level (P  0.042
by standardized Wilcoxon and Ansari–Bradley statistics).
Fig. 2. Relationship between amino acid substitutions in the ISDR and circulating viral loads, determined by the Amplicor-monitor method. The number of
amino acid substitutions in the ISDR correlated inversely with circulating viral loads (P  0.0001 by Spearmann’s rank test).
Fig. 3. ISDR sequences in the six patients whose full-length HCV sequences were determined. “High” and “Low” denote high and low viral load groups,
respectively.
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These results show that amino acid usage at aa 962 may
have an impact on circulating HCV RNA loads, even after
the status of ISDR amino acid substitution is corrected.
Discussion
In the present study, we analyzed initially the correlation
between amino acid substitutions in the ISDR and serum
viral load. Subsequently, we examined other regions that
may be associated with circulating viral loads in HCV-1b
infection. The findings can be summarized as two points.
First, the number of substitutions in the ISDR was inversely
correlated with circulating viral load. Second, in patients
with no or one amino acid substitution in the ISDR, amino
acid usage at aa 962 correlated with circulating viral load.
Patients with low circulating viral loads and with an
HCV genotype other than 1 tend to respond to IFN therapy
(Tubota et al., 1994; Kobayashi et al., 1994; Mita et al.,
1994; Hino et al., 1994; Pawlotsky et al., 1996; Yamada et
al., 1995). In chronic hepatitis attributable to HCV-1b, low
pretreatment circulating viral loads are closely associated
with effective IFN therapy (Tubota et al., 1994; Kobayashi
et al., 1994; Mita et al., 1994; Hino et al., 1994). Mean-
while, we reported that ISDR status is an independent factor
predicting an IFN effect (Enomoto et al., 1995, 1996; Ku-
rosaki et al., 1997). In Japan, most investigators have re-
ported data similar to ours concerning the relationship be-
tween ISDR mutations and IFN efficacy (Chayama et al.,
1997; Yoshioka et al., 2001). However, in Western coun-
tries, there have been some conflicting data (Khorsi et al.,
1997; Zeuzem et al., 1997; Squadrito et al, 1997). Recently,
a meta-analysis of studies in Western countires on this
subject demonstrated that a statistically significant correla-
tion was also found between IFN efficacy and ISDR muta-
tions by combining studies in Western counties that inde-
pendently were unable to detect such a correlation,
suggesting the importance of sample size (Witherell and
Beineke, 2001).
Consequently, the “mutant-type” ISDR correlates with a
low viral load (Enomoto et al., 1996; Chayama et al., 1997).
Furthermore, multiple amino acid substitutions in the ISDR
were detected only with low circulating viral load in a
longitudinal analysis of two patients whose circulating viral
loads fluctuated (Hashimoto et al., 1999). These observa-
tions suggest that amino acid substitutions in the ISDR
correlate with circulating viral level even in individual pa-
tients. In the present study, we confirmed that serum HCV
RNA load is inversely correlated with the number of amino
acid substitutions in the ISDR. This finding suggests that the
ISDR element of NS5A affects viral replication strongly by
an unknown mechanism, while some studies have demon-
strated a relationship between the amino acid sequence of
the ISDR and NS5A function. For example, we demon-
strated a difference in the transactivator activity of NS5A
according to the type of ISDR (Fukuma et al., 1998). As
another example, mutations in the ISDR were reported to
affect the interaction between NS5A and PKR (dsRNA-
dependent protein kinase) (Gale et al., 1997).
We demonstrated no differences in viral load between
patients with no and one ISDR substitution. Most of these
have an amino acid substitution at aa 2218 from histidine to
arginine, both of which are basic amino acids. This result
suggests that conservative substitution of aa 2218 does not
have a great effect on the function of the ISDR and both
histidine and arginine can be regarded essentially as same
for ISDR function.
Next, we examined sequence elements other than the
ISDR that may affect circulating viral loads in HCV infec-
tion. This is the first report that has analyzed full-length
HCV genomes in relation to viral loads. We analyzed six
full-length HCV sequences, all with functionally the same
ISDR. Four candidate residues were identified and analysis
revealed that only aa 962 in NS2 was closely associated
Fig. 4. At four amino acid positions (aa 708, 962, 1158, and 1641), amino acid usages differ consistently between the high and low viral load groups.
Neighboring amino acid residues also are shown for each position.
379H. Watanabe et al. / Virology 311 (2003) 376–383
Table 1
Amino acid usage at aa 708, aa 962, aa 1158, and aa 1641 in 67 chronic hepatitis C patients by HCV with 0 or 1 ISDR amino acid substitution
Patient No. aa 708
High titer group: A







HCV RNA (bDNA) ISDR mutation
1 A T I I 0.50 0
2 A M V V 0.50 0
3 A V V V 0.50 0
4 V T V I 0.50 0
5 A T V I 0.50 0
6 V V V I 0.50 0
7 A V I I 0.50 1
8 A V I A 0.50 1
9 V A I I 0.50 0
10 A A V I 0.50 0
11 A A V V 0.65 0
12 V A V I 0.68 0
13 A A V I 0.69 0
14 A A V I 0.75 0
15 A A V I 0.77 0
16 A A V I 0.77 1
17 A V V I 0.96 1
18 A A I V 1.0 0
19 A A V I 1.1 0
20 A A I I 1.1 0
21 A A V I 1.2 0
22 A A V V 1.3 1
23 A A V I 1.6 0
24 A K V I 1.6 0
25 A A V I 1.6 0
26 T A V I 1.8 0
27 A A V I 1.9 0
28 A A V I 2.1 0
29 A V V I 2.4 0
30 A A V I 2.8 0
31 A A I I 3.0 1
32 A A V V 3.2 0
33 A A V I 3.3 0
34 A A V V 3.6 1
35 V G V V 4.3 0
36 A A V I 4.6 1
37 A T V V 4.7 0
38 A S I I 5.5 0
39 V A V I 5.5 0
40 A A V I 6.0 0
41 A A V I 6.2 0
42 A T V I 7.5 0
43 A T I I 7.7 0
44 A A V I 7.8 0
45 A V V I 8.1 0
46 A A V I 8.2 0
47 A A V V 8.5 0
48 A A V I 9.2 0
49 V A V I 9.9 0
50 T A V I 11 0
51 A A V I 11 0
52 A A V V 11 0
53 A A V I 12 0
54 V A V I 13 0
55 A A V I 13 0
56 A A I T 13 0
57 A A V I 14 0
58 A A V I 14 0
59 A A I V 16 0
60 A V V I 17 1
61 A A I I 17 1
62 A A L I 20 0
63 A T V I 22 1
64 A A I I 27 0
65 A A I I 30 1
66 V A V I 40 0
67 A A V I 40 0
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with circulating viral load. This result suggests that the
genomic structure of NS2 may be involved in the mecha-
nism determining the circulating viral load.
The function of NS2 has not been clarified. NS2 is a
transmembrane polypeptide (Yamaga and Ou, 2002) and a
component of the virally encoded protease functioning in
association with the serine protease domain of NS3 (San-
tolini et al., 1995). One mutation study shows that aa 952
and aa 993 of the NS2 protein are essential for the NS3-
dependent cleavage between NS2 and NS3 (Grakoui et al.,
1993). Recently, we analyzed the sequence elements of
HCV affecting the natural course of chronic hepatitis C. We
found that aa 962 was one of seven amino acids affecting
the clinical course of hepatitis C (Nagayama et al., 2000).
Specifically, patients infected with HCV-1b carrying an
alanine at aa 962 suffered more frequently from advanced
disease, such as hepatocellular carcinoma and liver cirrho-
sis, than “non-alanine” patients. In the present study, alanine
at aa 962 was associated with a high viral load. This finding
suggests that patients with a high circulating viral load
undergo a more aggressive clinical course, although aa 962
is only one of the seven amino acids included in the count
for the progression score (Nagayama et al., 2000). More
recently, Takahashi et al. (2001) also confirmed aa 962 as
one of the elements contributing to the progression score,
further indicating the importance of the function of NS2.
Synthesis of both the replicative intermediate minus-
strand HCV RNA and the progeny positive-strand HCV
RNA is thought to occur via RNA-dependent RNA poly-
merase (RdRp) activity in NS5B protein (Behrens et al.,
1996; Yuan et al., 1997; Lohmann et al., 1997). Thus, NS5B
may be a key element in viral replication. However, in this
study, we did not find any sequence elements in NS5B that
were associated with circulating viral load. A precise ex-
planation for this result is difficult, but it is possible that a
major amino acid substitution in NS5B itself may make
HCV replication-defective, so that it cannot survive in the
host.
In conclusion, we demonstrated that the circulating viral
load of HCV-1b is inversely correlated with ISDR amino
acid substitutions. Furthermore, as a second sequence ele-
ment, aa 962 was identified as a critical determinant of viral
load by full-length sequence analysis of HCV. These clin-
ical observations may help further in vitro studies on the




We examined prospectively 226 patients with chronic
HCV infection between August 1996 and July 1998 at
Musashino Red Cross Hospital. All patients were positive
for serum HCV antibodies (third-generation assay) and
HCV RNA of genotype 1b (Okamoto et al., 1992; Sim-
monds et al., 1994). All patients were negative for serum
hepatitis B surface antigen, anti-HBc antibodies, and anti-
nuclear antibodies, and had no other causes of hepatitis
including excessive alcohol intake and hepatotoxic drugs.
No patient had received interferon therapy before the mea-
surement of viral load. We analyzed serum HCV RNA
levels and the ISDR amino acid sequence in these 226
patients. A branched-chain DNA (bDNA) assay (Quanti-
plex HCV RNA Version 1.0, Chiron, Emeryville, CA,
USA) (Lau et al., 1993) and the Amplicor monitor assay
(Version 1.0, Roche Diagnostic Systems, Basel, Switzer-
land) were used to measure circulating levels of HCV RNA.
The limits of detection for these assays were 0.5 million
genome equivalents per milliliter for bDNA and 1.0 kilo-
copies per milliliter for Amplicor monitor.
Subsequently, we determined the full-length HCV se-
quences detected in sera from six patients with chronic
hepatitis C attributable to HCV-1b that had no or one
substitution in the ISDR, to find regions other than the ISDR
associated with viral load, using the experimental proce-
dures described below. Of these patients, three had high
circulating viral load (15 MEq/ml by the bDNA method;
high-titer group) and the other three had low viral titer
(0.5 MEq/ml by the bDNA method; low-titer group).
After alignment of the six full-length sequences, amino acid
usage (for the coding region) and nucleotide usage (for the
noncoding regions) were compared. The frequently used
amino acid/nucleotide was identified for each residue, and,
if usage at a certain residue differed between the two titer
groups, that residue was regarded as potentially significant
for discrimination between the two groups.
After candidate residues were identified, for validation,
we examined another 67 patients with chronic hepatitis C
attributable to HCV-1b that had no or one amino acid
substitution in the ISDR. The patients were selected ran-
domly from the initial cohort of this study. HCV sequences
flanking the candidate residues were determined and amino
acid usage at each candidate residue was analyzed statisti-
cally as described below.
Sequence analysis of HCV
RNA was extracted from serum using a modified acid
guanidinium–phenol–chloroform method (Chomczynski
and Sacchi, 1987) using ISOGEN (Wako, Japan). Reverse
transcription polymerase chain reaction (RT-PCR) was per-
formed as described previously (Enomoto et al., 1994).
Table 2
Difference in median HCV RNA load (MEq/ml) between patients with
high-titer and low-titer-type amino acids
aa 708 aa 962 aa 1158 aa 1641
Median HCV RNA load (MEq/ml)
High-titer type 3.6 5.2 3.5 4.6
Low-titer type 4.3 1.6 5.5 3.4
P value NS 0.042 NS NS
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Briefly, RNA extracted from 150 l of serum was reverse-
transcribed to cDNA using random hexamers. The full-
length HCV genome, except the poly U stretch, was ampli-
fied with 21 partially overlapping primer sets using nested
PCR. The cDNA was used for the first-round PCR. Details
were shown previously (Enomoto et al., 1994). Each PCR
product was purified, and the residual primers were re-
moved using a spin filtration column (Suprec 02, Takara,
Kyoto, Japan) according to the manufacturer’s instructions.
Thereafter, both strands of the PCR products were cycle-
sequenced using a PRISM dye termination kit (CN402069,
Applied Biosystems, Japan) according to the manufacturer’s
instruction. The sequencing primers were the M13 forward
primer for the sense strand and the M13 reverse primer for
the antisense strand. The products were purified using a
Quickspin column (Boeringer-Mannheim, Indianapolis, IN,
USA) and sequenced automatically (Model 373S, Applied
Biosystems Japan). Nucleotide and predicted amino acid
sequences, including the ISDR, were compared with the
sequence of HCV-J (Kato et al., 1990) as a reference. Types
of ISDR (wild, intermediate, and mutant type) were defined
as in our previous report (Enomoto et al., 1996). Sequencing
was performed in duplicate. This ruled out the possibility of
misincorporation of nucleotides during PCR.
Statistical analysis
Distributions of continuous variables were analyzed us-
ing standardized Wilcoxon and Ansari–Bradley statistics
(Lepage’s test) (Lepage, 1971; Hirakawa, 1974). The cor-
relation between the number of amino acid substitutions in
NS5A and serum HCV RNA level was examined by Spear-
man’s rank correlation test using Statview 5.0 software
(Abacus Concepts, Berkeley, CA, USA). All tests of signif-
icance were two-tailed and P values less than 0.05 were
considered to be statistically significant.
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